Evaluating an alternative oral regimen for the treatment of polymyalgia rheumatica

Journal of Clinical Rheumatology

Volumn 6, Issue 2, 2000, Pages 61-64

  Meyerhoff, John ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Polymyalgia drug therapy

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; PREDNISONE;

ARTICLE; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RHEUMATIC POLYMYALGIA; TREATMENT OUTCOME;

EID: 0034052817     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/00124743-200004000-00001     Document Type: Article

References (17)

1. Hazelman BJ. Polymyalgia rheumatica. In: Klippel JH, Dieppe PA, editors. Rheumatology. 2nd ed. London: Mosby; 1998. p. 7.21.1-8.
2. Hunder GG. Polymyalgia rheumatica. Up to Date [CD-ROM]. Version 6.2. 1998. Rose BD.
3. Weyand CM, Goronzy JJ. Polymyalgia rheumatica and giant cell arteritis. In: Koopman W J, editor. Arthritis and allied conditions 13th ed. Baltimore: Williams & Wilkins; 1997. pp. 1605-16.
4. Gardner GC. Polymyalgia rheumatica, temporal (giant cell) arteritis and Takayasu's arteritis. In: Weisman MH, Weinblatt ME, editors. Treatment of the rheumatic diseases. Philadelphia: WB Saunders; 1995. p. 158-71.
5. Salvarani C, Macchioni P, Boiardi L. Polymyalgia rheumatica. Lancet 1997;350:43-7.
6. Behn AR, Perera T, Myles AB. Polymyalgia rheumatica and corticosteroids: how much for how long. Ann Rheum Dis 1983;42:374-8.
7. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988;47:733-9.
8. Kyle V, Hazelman BL. Treatment of polymyalgia rheumatics and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989;48:658-61.
9. Meyerhoff J. Rapid tapering of initial prednisone dose in polymyalgia rheumatica. Arthritis Rheum 1998;41:S261.
10. Osborn T, Ropos T. Treatment of polymyalgia rheumatica during the first six months: a comparison of two steroid regimens. Arthritis Rheum 1998;41.
11. Dean AG, Dean AJ, Coulombier D, Brendel KA, Smith DC, Burton AH, et al. Epi Info: a word processing, database, and statistics program for epidemiology on microcomputers. In: 6.04b ed. Atlanta: Centers for Disease Control and Prevention; 1997.
12. Bird HA, Esselinck VV, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38: 434-9.
13. Weyand C, Fulbright J, Evans J, Hunder G, Goronzy J. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999; 159:577-84.
14. Kyle V, Hazleman B. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between sleroid dose and steroid side effects. Ann Rheum Dis 1989;48:662-6.
15. Ayoub WT, Franklin C M., Torretti D. Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 1985;79:309-15.
16. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica. J Rheumatol 1990;17:1340-5.
17. Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. Bull Rheum Dis 1998;47:2-7.